Table 3.
Treatments during admission and complications of patients with AF and COVID-19, classified as deceased and not deceased.
| Deceased N = 738 (%) | Not deceased N = 1061 (%) | p | |
|---|---|---|---|
| Treatments during admission | |||
| ACEI | 82 (11.2) | 124 (11.8) | 0.724 |
| ARBs | 91 (12.6) | 195 (18.6) | <0.01 |
| ASA | 75 (10.4) | 96 (9.2) | 0.396 |
| Statins | 109 (15.0) | 240 (2.9) | <0.01 |
| Ibuprofen | 1 (0.1) | 11 (1.0) | 0.04 |
| Other NSAIDs | 20 (2.8) | 37 (3.5) | 0.03 |
| Corticosteroids | 320 (43.8) | 387 (35.9) | <0.01 |
| Lopinavir/ritonavir | 302 (41.2) | 481 (44.5) | 0.17 |
| Remdesivir | 2 (0.3) | 15 (1.4) | <0.01 |
| Hydroxychloroquine | 500 (68.4) | 878 (81.1) | <0.01 |
| Chloroquine | 27 (3.7) | 33 (3.1) | 0.46 |
| Colchicine | 10 (1.4) | 9 (0.8) | 0.28 |
| Tocilizumab | 33 (4.5) | 46 (4.3) | 0.79 |
| Complications | |||
| Prone | 93 (12.7) | 58 (5.5) | <0.01 |
| NIMV | 58 (7.9) | 35 (3.3) | <0.01 |
| IMV | 47 (6.4) | 26 (2.5) | <0.01 |
| HFO | 85 (11.7) | 48 (4.6) | <0.01 |
| Bacterial pneum. | 149 (20.2) | 130 (12.3) | <0.01 |
| ARDS | 391 (53.4) | 49 (4.6) | <0.01 |
| HF | 208 (28.2) | 157 (14.8) | <0.01 |
| AMI | 23 (3.1) | 6 (0.6) | <0.01 |
| AKF | 279 (37.9) | 174 (16.4) | <0.01 |
| PTE | 4 (0.5) | 8 (0.8) | 0.578 |
ASA: acetylsalicylic acid; NSAIDs: nonsteroidal anti-inflammatory drugs; ARBs: angiotensin receptor blockers; AMI: acute myocardial infarction; HF: heart failure; ACEI: angiotensin converting enzyme inhibitors; AKF: acute kidney failure; HFO: high-flow oxygen therapy; ARDS: acute respiratory distress syndrome; PTE: pulmonary thromboembolism; IMV: invasive mechanical ventilation; NIMV: Non-invasive mechanical ventilation.